Evidence map›Paper›PMID 37780100›Full record

ArticleThe journal of allergy and clinical immunology. Global2023

Efficacy of dupilumab for the treatment of severe skin disease in cytotoxic T lymphocyte antigen-4 insufficiency: A role of type 2 inflammation?

L Karla Arruda, Daniel L Cordeiro, Sarah S Langer, Marcel Koenigham-Santos, Rodrigo T Calado, Marina M Dias, Leonardo R Anhesini, João Bosco Oliveira, Bodo Grimbacher, Mariana P L Ferriani

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of allergy and clinical immunology. Global, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

L Karla ArrudaDepartment of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Daniel L CordeiroDepartment of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Sarah S LangerDepartment of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Marcel Koenigham-SantosDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Rodrigo T CaladoDepartment of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Marina M DiasDepartment of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Leonardo R AnhesiniIntensive Care Unit, Hospital São Paulo, São Paulo, Brazil.
João Bosco OliveiraHospital Israelita Albert Einstein, São Paulo, Brazil.
Bodo GrimbacherInstitute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany.
Mariana P L FerrianiDepartment of Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil.
Universidade de São Paulo · BRHospital Israelita Albert Einstein · BRHospital São Paulo · BRUniversity Medical Center Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report on the successful treatment of a severe, recalcitrant dermatitis caused by CTLA-4 insufficiency with dupilumab, raising the possibility of a role of type 2 immunity in clinical conditions associated with CTLA-4 insufficiency.

Indexed as

abataceptcytotoxic T-lymphocyte antigen-4 insufficiencyDermatitisdupilumabinborn errors of immunity

Identifiers

PMID37780100
PMCPMC10509893
OpenAlexW4296628482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.